The number of thyroid cancers is increasing. Standard treatment usually includes primary
surgery, thyroid-stimulating hormone suppressive therapy, and ablation of the thyroid …

Even though differentiated thyroid carcinoma is a slow growing and usually curable disease,
recurrence occurs in 20-40% and cellular dedifferentiation in up to 5% of cases …

Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence has
increased over the last few decades. It derives from follicular thyroid cells. Generally …

The morbidity of thyroid cancer is increasing gradually year by year, showing an increasing
tendency in nationality, sex, age, tumor size, and tumor staging. The changes of thyroid cell …

This Special Issue (SI)“Recent Advances in Thyroid Cancer Research” covers research
articles and reviews in the field of thyroid cancer research. It includes publications reporting …

The spectrum of thyroid cancers ranges from one of the most indolent to one of the most
aggressive solid tumors identified. Conventional therapies for thyroid cancers are based on …

Advanced thyroid cancer refers to thyroid tumors which are resistant to conventional
therapies and do not respond to radioiodine and comprises metastatic or recurrent …

Although the majority of papillary thyroid carcinoma could be successfully managed by
complete surgical resection alone or resection followed by radioiodine ablation, a small …

Differentiated thyroid carcinoma (DTC) accounts for more than 90% of new thyroid cancer
diagnoses, and includes papillary, follicular and Hürthle cell carcinoma. The prognosis for …

Thyroid carcinomas are rare and heterogeneous diseases representing less than 1% of all
malignancies. The majority of thyroid carcinomas are differentiated entities (papillary and …